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Tacrine is an acetylcholinesterase inhibitor used as cognitive enhancer in Alzheimer's 
disease treatment. However, the low therapeutic efficiency and the high incidence of side 
effects have limited its clinical use. In the present study, the molecular mechanisms 
underlying the brain activity of tacrine and two novel tacrine analogues (T1, T2) were 
approached focusing on three aspects: i) effects on brain cholinesterase activity; ii) 
perturbations on electron transport chain enzymes activities of non-synaptic brain 
mitochondria; iii) the role of mitochondrial lipidome changes induced by these compounds 
on the mitochondrial bioenergetics. The brain effects were evaluated 18 hours after a single 
dose (75.6 moles/Kg) administration of tacrine or tacrine-analogues. The three compounds 
promoted a significant reduction of brain acetylcholinesterase and butyrylcholinesterase 
activities. Additionally, tacrine showed to be more efficient in brain acetylcholinesterase 
inhibition than T2 tacrine-analogue and less active than T1 tacrine-analogue, while the 
butyrylcholinesterase inhibition follows the order: T1 > T2 > tacrine. The studies with 
nonsynaptic brain mitochondria show that all the compounds studied disturbed the brain 
mitochondrial bioenergetics mainly by inhibition of complex I activity. Furthermore, the 
activity of complex IV is also affected by tacrine and T1 treatments while FoF1ATPase is 
only affected by tacrine. Therefore, the compounds toxicity to the brain mitochondria, that 
follow the order: tacrine >> T1 > T2, does not correlate with their ability to inhibit brain 
cholinesterase enzymes. Lipidomics approaches show that phosphatidylethanolamine is the 
most abundant phospholipid class in non-synaptic brain mitochondria and cardiolipin 
present greater diversity of molecular species. Tacrine induced significant perturbations in 
mitochondrial phospholipid profile detected by changes in relative abundance of 
phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol and cardiolipin and 
by the presence of oxidized phosphatidylserines. Additionally, in both T1 and T2 groups, 
the lipid content and molecular composition of brain mitochondria phospholipids are 
perturbed in less extent than in the tacrine group. The abnormalities in cardiolipin content 
and the amount of oxidized phosphatidylserines were associated with significant reductions 
in mitochondrial enzymes activities, mainly complex I. These results indicate that tacrine 
and its analogues impair the mitochondrial function and bioenergetics, compromising the 
activity of brain cells. 
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